BioLegend FY2020 audited: revenue $241.9M, net income $90.6M

REVVITY, INC.

BioLegend net sales $241.9M, gross profit $169.7M, operating income $109.6M, net income $90.2M.
Total assets $465.9M at Dec 31, 2020; cash $134.4M, short-term investments $90.0M.
Pro forma combined financials for PerkinElmer and BioLegend for FY2020 and H1 2021 filed.
Acquisition completed Sept 17, 2021 via merger of wholly owned subsidiaries.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.